1
|
Denechaud M, Geurs S, Comptdaer T, Bégard S, Garcia-Núñez A, Pechereau LA, Bouillet T, Vermeiren Y, De Deyn PP, Perbet R, Deramecourt V, Maurage CA, Vanderhaegen M, Vanuytven S, Lefebvre B, Bogaert E, Déglon N, Voet T, Colin M, Buée L, Dermaut B, Galas MC. Tau promotes oxidative stress-associated cycling neurons in S phase as a pro-survival mechanism: Possible implication for Alzheimer's disease. Prog Neurobiol 2023; 223:102386. [PMID: 36481386 DOI: 10.1016/j.pneurobio.2022.102386] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2022] [Revised: 11/24/2022] [Accepted: 12/02/2022] [Indexed: 12/12/2022]
Abstract
Multiple lines of evidence have linked oxidative stress, tau pathology and neuronal cell cycle re-activation to Alzheimer's disease (AD). While a prevailing idea is that oxidative stress-induced neuronal cell cycle reactivation acts as an upstream trigger for pathological tau phosphorylation, others have identified tau as an inducer of cell cycle abnormalities in both mitotic and postmitotic conditions. In addition, nuclear hypophosphorylated tau has been identified as a key player in the DNA damage response to oxidative stress. Whether and to what extent these observations are causally linked remains unclear. Using immunofluorescence, fluorescence-activated nucleus sorting and single-nucleus sequencing, we report an oxidative stress-associated accumulation of nuclear hypophosphorylated tau in a subpopulation of cycling neurons confined in S phase in AD brains, near amyloid plaques. Tau downregulation in murine neurons revealed an essential role for tau to promote cell cycle progression to S phase and prevent apoptosis in response to oxidative stress. Our results suggest that tau holds oxidative stress-associated cycling neurons in S phase to escape cell death. Together, this study proposes a tau-dependent protective effect of neuronal cell cycle reactivation in AD brains and challenges the current view that the neuronal cell cycle is an early mediator of tau pathology.
Collapse
Affiliation(s)
- Marine Denechaud
- University of Lille, Inserm, CHU Lille, CNRS, LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France.
| | - Sarah Geurs
- Department of Biomolecular Medicine, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium; Department of Human Genetics, University of Leuven (KU Leuven), 3000 Leuven, Belgium.
| | - Thomas Comptdaer
- University of Lille, Inserm, CHU Lille, CNRS, LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France.
| | - Séverine Bégard
- University of Lille, Inserm, CHU Lille, CNRS, LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France.
| | - Alejandro Garcia-Núñez
- University of Lille, Inserm, CHU Lille, CNRS, LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France.
| | - Louis-Adrien Pechereau
- University of Lille, Inserm, CHU Lille, CNRS, LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France.
| | - Thomas Bouillet
- University of Lille, Inserm, CHU Lille, CNRS, LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France.
| | - Yannick Vermeiren
- Laboratory of Neurochemistry and Behavior, and Biobank, Institute Born-Bunge, University of Antwerp, Universiteitsplein 1, BE-2610 Antwerpen, Belgium.
| | - Peter P De Deyn
- Laboratory of Neurochemistry and Behavior, and Biobank, Institute Born-Bunge, University of Antwerp, Universiteitsplein 1, BE-2610 Antwerpen, Belgium; Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, eindendreef 1, 2020 Antwerpen, Belgium.
| | - Romain Perbet
- University of Lille, Inserm, CHU Lille, CNRS, LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France.
| | - Vincent Deramecourt
- University of Lille, Inserm, CHU Lille, CNRS, LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France; Department of Pathological Anatomy, University of Lille, CHU Lille, Lille, France.
| | - Claude-Alain Maurage
- University of Lille, Inserm, CHU Lille, CNRS, LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France; Department of Pathological Anatomy, University of Lille, CHU Lille, Lille, France.
| | - Michiel Vanderhaegen
- Department of Human Genetics, University of Leuven (KU Leuven), 3000 Leuven, Belgium.
| | - Sebastiaan Vanuytven
- Department of Human Genetics, University of Leuven (KU Leuven), 3000 Leuven, Belgium.
| | - Bruno Lefebvre
- University of Lille, Inserm, CHU Lille, CNRS, LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France.
| | - Elke Bogaert
- Department of Biomolecular Medicine, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium.
| | - Nicole Déglon
- Lausanne University Hospital (CHUV) and University of Lausanne, Neuroscience Research Center (CRN), Laboratory of Cellular and Molecular Neurotherapies, 1011 Lausanne, Switzerland.
| | - Thierry Voet
- Department of Human Genetics, University of Leuven (KU Leuven), 3000 Leuven, Belgium; KU Leuven, Institute for Single Cell Omics (LISCO), KU Leuven, 3000 Leuven, Belgium.
| | - Morvane Colin
- University of Lille, Inserm, CHU Lille, CNRS, LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France.
| | - Luc Buée
- University of Lille, Inserm, CHU Lille, CNRS, LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France.
| | - Bart Dermaut
- Center for Medical Genetics, Ghent University Hospital, 9000 Ghent, Belgium; Department of Biomolecular Medicine, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium.
| | - Marie-Christine Galas
- University of Lille, Inserm, CHU Lille, CNRS, LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France.
| |
Collapse
|
2
|
Bouillet T, Ciba M, Alves CL, Rodrigues FA, Thielemann C, Colin M, Buée L, Halliez S. Revisiting the involvement of tau in complex neural network remodeling: analysis of the extracellular neuronal activity in organotypic brain slice co-cultures. J Neural Eng 2022; 19. [PMID: 36374001 DOI: 10.1088/1741-2552/aca261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2022] [Accepted: 11/14/2022] [Indexed: 11/16/2022]
Abstract
Objective.Tau ablation has a protective effect in epilepsy due to inhibition of the hyperexcitability/hypersynchrony. Protection may also occur in transgenic models of Alzheimer's disease by reducing the epileptic activity and normalizing the excitation/inhibition imbalance. However, it is difficult to determine the exact functions of tau, because tau knockout (tauKO) brain networks exhibit elusive phenotypes. In this study, we aimed to further explore the physiological role of tau using brain network remodeling.Approach.The effect of tau ablation was investigated in hippocampal-entorhinal slice co-cultures during network remodeling. We recorded the spontaneous extracellular neuronal activity over 2 weeks in single-slice cultures and co-cultures from control andtauKOmice. We compared the burst activity and applied concepts and analytical tools intended for the analysis of the network synchrony and connectivity.Main results.Comparison of the control andtauKOco-cultures revealed that tau ablation had an anti-synchrony effect on the hippocampal-entorhinal two-slice networks at late stages of culture, in line with the literature. Differences were also found between the single-slice and co-culture conditions, which indicated that tau ablation had differential effects at the sub-network scale. For instance, tau ablation was found to have an anti-synchrony effect on the co-cultured hippocampal slices throughout the culture, possibly due to a reduction in the excitation/inhibition ratio. Conversely, tau ablation led to increased synchrony in the entorhinal slices at early stages of the co-culture, possibly due to homogenization of the connectivity distribution.Significance.The new methodology presented here proved useful for investigating the role of tau in the remodeling of complex brain-derived neural networks. The results confirm previous findings and hypotheses concerning the effects of tau ablation on neural networks. Moreover, the results suggest, for the first time, that tau has multifaceted roles that vary in different brain sub-networks.
Collapse
Affiliation(s)
- Thomas Bouillet
- University Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, Lille F-59000, France
| | - Manuel Ciba
- BioMEMS Lab, University of Applied Sciences Aschaffenburg, Aschaffenburg 63743, Germany
| | - Caroline Lourenço Alves
- BioMEMS Lab, University of Applied Sciences Aschaffenburg, Aschaffenburg 63743, Germany.,Institute of Mathematics and Computer Science, University of São Paulo, São Carlos SP 13566-590, Brazil
| | | | - Christiane Thielemann
- BioMEMS Lab, University of Applied Sciences Aschaffenburg, Aschaffenburg 63743, Germany
| | - Morvane Colin
- University Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, Lille F-59000, France
| | - Luc Buée
- University Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, Lille F-59000, France
| | - Sophie Halliez
- University Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, Lille F-59000, France
| |
Collapse
|
3
|
Leroux E, Perbet R, Caillierez R, Richetin K, Lieger S, Espourteille J, Bouillet T, Bégard S, Danis C, Loyens A, Toni N, Déglon N, Deramecourt V, Schraen-Maschke S, Buée L, Colin M. Extracellular vesicles: Major actors of heterogeneity in tau spreading among human tauopathies. Mol Ther 2022; 30:782-797. [PMID: 34563677 PMCID: PMC8821971 DOI: 10.1016/j.ymthe.2021.09.020] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2021] [Revised: 07/12/2021] [Accepted: 09/20/2021] [Indexed: 02/04/2023] Open
Abstract
Tauopathies are neurodegenerative diseases characterized by tau inclusions in brain cells. Seed-competent tau species have been suggested to spread from cell to cell in a stereotypical manner, indicating that this may involve a prion-like mechanism. Although the intercellular mechanisms of transfer are unclear, extracellular vesicles (EVs) could be potential shuttles. We assessed this in humans by preparing vesicles from fluids (brain-derived enriched EVs [BD-EVs]). These latter were isolated from different brain regions in various tauopathies, and their seeding potential was assessed in vitro and in vivo. We observed considerable heterogeneity among tauopathies and brain regions. The most striking evidence was coming mainly from Alzheimer's disease where the BD-EVs clearly contain pathological species that can induce tau lesions in vivo. The results support the hypothesis that BD-EVs participate in the prion-like propagation of tau pathology among tauopathies, and there may be implications for diagnostic and therapeutic strategies.
Collapse
Affiliation(s)
- Elodie Leroux
- Université de Lille, INSERM, CHU-Lille, Lille Neuroscience & Cognition, 59000 Lille, France
| | - Romain Perbet
- Université de Lille, INSERM, CHU-Lille, Lille Neuroscience & Cognition, 59000 Lille, France
| | - Raphaëlle Caillierez
- Université de Lille, INSERM, CHU-Lille, Lille Neuroscience & Cognition, 59000 Lille, France
| | - Kevin Richetin
- Department of Psychiatry, Center for Psychiatric Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, 1011 Lausanne, Switzerland,Lausanne University Hospital (CHUV) and University of Lausanne, Neuroscience Research Center (CRN), Laboratory of Cellular and Molecular Neurotherapies, 1011 Lausanne, Switzerland,Lausanne University Hospital (CHUV) and University of Lausanne, Department of Clinical Neuroscience (DNC), Laboratory of Cellular and Molecular Neurotherapies, 1011 Lausanne, Switzerland
| | - Sarah Lieger
- Université de Lille, INSERM, CHU-Lille, Lille Neuroscience & Cognition, 59000 Lille, France
| | - Jeanne Espourteille
- Department of Psychiatry, Center for Psychiatric Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, 1011 Lausanne, Switzerland
| | - Thomas Bouillet
- Université de Lille, INSERM, CHU-Lille, Lille Neuroscience & Cognition, 59000 Lille, France
| | - Séverine Bégard
- Université de Lille, INSERM, CHU-Lille, Lille Neuroscience & Cognition, 59000 Lille, France
| | - Clément Danis
- Université de Lille, INSERM, CHU-Lille, Lille Neuroscience & Cognition, 59000 Lille, France
| | - Anne Loyens
- Université de Lille, INSERM, CHU-Lille, Lille Neuroscience & Cognition, 59000 Lille, France
| | - Nicolas Toni
- Department of Psychiatry, Center for Psychiatric Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, 1011 Lausanne, Switzerland
| | - Nicole Déglon
- Lausanne University Hospital (CHUV) and University of Lausanne, Neuroscience Research Center (CRN), Laboratory of Cellular and Molecular Neurotherapies, 1011 Lausanne, Switzerland,Lausanne University Hospital (CHUV) and University of Lausanne, Department of Clinical Neuroscience (DNC), Laboratory of Cellular and Molecular Neurotherapies, 1011 Lausanne, Switzerland
| | - Vincent Deramecourt
- Université de Lille, INSERM, CHU-Lille, Lille Neuroscience & Cognition, 59000 Lille, France
| | | | - Luc Buée
- Université de Lille, INSERM, CHU-Lille, Lille Neuroscience & Cognition, 59000 Lille, France,Corresponding author: Luc Buée, PhD, Université de Lille, INSERM, CHU-Lille, Lille Neuroscience & Cognition, Bâtiment Biserte, rue Polonovski, 59045 Lille Cedex, France.
| | - Morvane Colin
- Université de Lille, INSERM, CHU-Lille, Lille Neuroscience & Cognition, 59000 Lille, France,Corresponding author: Morvane Colin, Université de Lille, INSERM, CHU-Lille, Lille Neuroscience & Cognition, Bâtiment Biserte, rue Polonovski, 59045 Lille Cedex, France.
| |
Collapse
|
4
|
Vanlemmens L, Mocaer H, Ginsbourger T, Descotes J, Masselin N, Deroubaix H, Fabre C, Devriendt J, Bouillet T, Lartigau E. Benefits of physical activity and sport integrated into the care pathway of oncology patient. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
5
|
Bouillet T, Bigard X, Brami C, Chouahnia K, Copel L, Dauchy S, Delcambre C, Descotes J, Joly F, Lepeu G, Marre A, Scotte F, Spano J, Vanlemmens L, Zelek L. Role of physical activity and sport in oncology. Crit Rev Oncol Hematol 2015; 94:74-86. [DOI: 10.1016/j.critrevonc.2014.12.012] [Citation(s) in RCA: 48] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2013] [Revised: 11/17/2014] [Accepted: 12/22/2014] [Indexed: 12/12/2022] Open
|
6
|
Phelip J, Vanlemmens L, Dilhuydy M, Artru P, Bouillet T, Audigier-Valette C, Caroli-Bosc F, Curé H, Ganem G, Greillier L, Laplaige P, Marre A, Quittet P, Rouby P, Scotte F. Patients' Vs Oncologists' Perception of Supportive Care in Cancer: Results of the French National Panach Survey. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu352.5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Landre T, Chouahnia K, Pailler MC, Bouillet T, Andriambololona V, Zelek I, Sebbane G, Guetz GD. Impact of co-morbidities on gemcitabine as single agent chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC). J Geriatr Oncol 2013. [DOI: 10.1016/j.jgo.2013.09.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
8
|
Boiron C, Bouillet T, Calmels P, Dauchy S, Duret J, Pavic M, Scotté F, Serin D. Bénéfices sur la survie de l’activité physique avant ou après un cancer du sein. ONCOLOGIE 2011. [DOI: 10.1007/s10269-011-2091-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
9
|
Bouillet T. Benefits of exercise for cancer patients. Ann Phys Rehabil Med 2011. [DOI: 10.1016/j.rehab.2011.07.507] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
10
|
Bouillet T. Apport de l’activité physique en cancérologie. Ann Phys Rehabil Med 2011. [DOI: 10.1016/j.rehab.2011.07.500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
11
|
Zelek L, Bouillet T, Latino-Martel P, Pecollo N, Barrandon E, Czernichow S, Galan P, Hercberg S. Mode de vie et cancer du sein: quels conseils pour la prise en charge de l’après cancer ? ONCOLOGIE 2010. [DOI: 10.1007/s10269-010-1878-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
12
|
Des Guetz G, Bouillet T, Wind P, Morere JF. Tolerance and efficacy of adjuvant chemoradiotherapy with FOLFIRI in adenocarcinoma of stomach and GI junction. Gastroenterol Clin Biol 2008; 32:875-876. [PMID: 18487031 DOI: 10.1016/j.gcb.2008.02.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/16/2007] [Revised: 02/19/2008] [Accepted: 02/28/2008] [Indexed: 05/26/2023]
|
13
|
Mariani P, Des Guetz G, Uzzan B, Nicolas P, Chouahnia K, Bouillet T, Perret G, Morère J. Systemic or hepatic arterial chemotherapy after curative resection of liver metastases from colorectal cancer. A meta-analysis of randomized controlled trials. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4077] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
14
|
Des Guetz G, Bouillet T, Etessami R, Diana C, Labrune S, Gervais R, Virally J, Hamond K, Spano JP, Sebbane G, Valeyre D, Morere JF. P.10 Evaluation of standard chemo-radiotherapy in older patients with locally advanced non-small cell lung cancer (NSCLC) enrolled in a multicenter randomized phase II study. Crit Rev Oncol Hematol 2007. [DOI: 10.1016/s1040-8428(13)70183-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
15
|
Bouillet T, Nizri D, Zawadi A, Herman D, Cupissol D, Demaux H, Touboul E, Cretin J, Morere JF. A randomized phase II study of concomitant CT (docetaxel±cisplatin) and (RT) in first-line treatment of locally advanced head and neck cancer (LAHNC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.6047] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6047 Background: 4 randomized trials demonstrated superiority of concomitant CT and radiotherapy (CRT) versus RT. Radiosensitizing effect of docetaxel showed in vitro, phase I recommended docetaxel dose as weekly 20 mg/m2 with concomitant RT. Methods: (pts) with inoperable LAHNC (T3/T4); PS < 2.RT in both arms was 70 Gy. In arm A, pts received 7 cycles of weekly Docetaxel 20 mg/m2 before RT and cisplatin 20 mg/m2 D1–3 every three weeks (3 cycles). In arm B, docetaxel alone at the same dose as in arm A.G-CSF secondary prophylaxis and ciprofloxacin recommended in both arms. Primary objective was WHO objective response rate (ORR). Statistical analysis: 2 steps according to a Simon plan authorized early interruption in case of insufficient efficacy. Results: 82 pts treated (Arms A/B:35/47); Arm A stopped in the first step. 47 pts treated in arm B. M/F (%) (83/17), median age 56.6 y, PS 0/1 (%) 54/46, T2/T3/T4 (%) 2/36/62, N0–1/N2/N3 (%) 30/55/15, primary site (%): buccal cavity (38), hypo-oropharynx (47), larynx (11). Median nbr of cycles 7 (3–7), 85% of pts completed planned CRT. ITT ORR: 89 % [75–96], median TTP 31.3 [19.3 –42.4], median OS 36.8 [21.2–49.5] months. Main grade 3–4 toxicities were mucositis (31.9%),skin toxicity (21.3%). Grade 3–4 hematological, GI and neurological toxicities were not observed. Conclusions: In this study, concomitant RT and weekly 20 mg/m2 docetaxel is effective and well tolerated in LAHNC. The docetaxel/cisplatin arm was prematurely discontinued for insufficient efficacy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- T. Bouillet
- Hopital Des Peupliers, Paris, France; Hôpital Pitié Salpétrière, Paris, France; Centre Hospitalier La Roche Sur Yon, La Roche Sur Yon, France; Hospital Robert Ballanger, Aulnay sous Bois, France; Centre Val d’Aurelle, Montpellier, France; Hospital Saint André, Bordeaux, France; Hospital Tenon, Paris, France; Clinique Valdegour, Nimes, France; CHU Avicenne, Bobigny, France
| | - D. Nizri
- Hopital Des Peupliers, Paris, France; Hôpital Pitié Salpétrière, Paris, France; Centre Hospitalier La Roche Sur Yon, La Roche Sur Yon, France; Hospital Robert Ballanger, Aulnay sous Bois, France; Centre Val d’Aurelle, Montpellier, France; Hospital Saint André, Bordeaux, France; Hospital Tenon, Paris, France; Clinique Valdegour, Nimes, France; CHU Avicenne, Bobigny, France
| | - A. Zawadi
- Hopital Des Peupliers, Paris, France; Hôpital Pitié Salpétrière, Paris, France; Centre Hospitalier La Roche Sur Yon, La Roche Sur Yon, France; Hospital Robert Ballanger, Aulnay sous Bois, France; Centre Val d’Aurelle, Montpellier, France; Hospital Saint André, Bordeaux, France; Hospital Tenon, Paris, France; Clinique Valdegour, Nimes, France; CHU Avicenne, Bobigny, France
| | - D. Herman
- Hopital Des Peupliers, Paris, France; Hôpital Pitié Salpétrière, Paris, France; Centre Hospitalier La Roche Sur Yon, La Roche Sur Yon, France; Hospital Robert Ballanger, Aulnay sous Bois, France; Centre Val d’Aurelle, Montpellier, France; Hospital Saint André, Bordeaux, France; Hospital Tenon, Paris, France; Clinique Valdegour, Nimes, France; CHU Avicenne, Bobigny, France
| | - D. Cupissol
- Hopital Des Peupliers, Paris, France; Hôpital Pitié Salpétrière, Paris, France; Centre Hospitalier La Roche Sur Yon, La Roche Sur Yon, France; Hospital Robert Ballanger, Aulnay sous Bois, France; Centre Val d’Aurelle, Montpellier, France; Hospital Saint André, Bordeaux, France; Hospital Tenon, Paris, France; Clinique Valdegour, Nimes, France; CHU Avicenne, Bobigny, France
| | - H. Demaux
- Hopital Des Peupliers, Paris, France; Hôpital Pitié Salpétrière, Paris, France; Centre Hospitalier La Roche Sur Yon, La Roche Sur Yon, France; Hospital Robert Ballanger, Aulnay sous Bois, France; Centre Val d’Aurelle, Montpellier, France; Hospital Saint André, Bordeaux, France; Hospital Tenon, Paris, France; Clinique Valdegour, Nimes, France; CHU Avicenne, Bobigny, France
| | - E. Touboul
- Hopital Des Peupliers, Paris, France; Hôpital Pitié Salpétrière, Paris, France; Centre Hospitalier La Roche Sur Yon, La Roche Sur Yon, France; Hospital Robert Ballanger, Aulnay sous Bois, France; Centre Val d’Aurelle, Montpellier, France; Hospital Saint André, Bordeaux, France; Hospital Tenon, Paris, France; Clinique Valdegour, Nimes, France; CHU Avicenne, Bobigny, France
| | - J. Cretin
- Hopital Des Peupliers, Paris, France; Hôpital Pitié Salpétrière, Paris, France; Centre Hospitalier La Roche Sur Yon, La Roche Sur Yon, France; Hospital Robert Ballanger, Aulnay sous Bois, France; Centre Val d’Aurelle, Montpellier, France; Hospital Saint André, Bordeaux, France; Hospital Tenon, Paris, France; Clinique Valdegour, Nimes, France; CHU Avicenne, Bobigny, France
| | - J. F. Morere
- Hopital Des Peupliers, Paris, France; Hôpital Pitié Salpétrière, Paris, France; Centre Hospitalier La Roche Sur Yon, La Roche Sur Yon, France; Hospital Robert Ballanger, Aulnay sous Bois, France; Centre Val d’Aurelle, Montpellier, France; Hospital Saint André, Bordeaux, France; Hospital Tenon, Paris, France; Clinique Valdegour, Nimes, France; CHU Avicenne, Bobigny, France
| |
Collapse
|
16
|
Coscas Y, Serin D, Cals L, Eisinger F, Blay J, Rixe O, Pivot X, Bouillet T, Roussel C, Morere J. Impact of organization of colorectal cancer screening: Results of EDIFICE study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.6078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6078 Background: The EDIFICE study aimed to allow better understanding of population’s adhesion to the tests available for the 4 most frequent cancers: breast, colorectal, prostate and lung. In 1998 the French National Consensus Conference advocated for mass cancer screening (CS) using Hemoccult II. The departments are divided according to the existence or not of an organized program: this screening was organized in 22 departments (3 “scout” started in 1998, 9 “first wave” in 2003 and 12 “second wave” in 2004). Results are reported hereunder. Methods: This first nationwide observational study was carried out in France from January 18th to February 2nd, 2005 among a representative sample of 1504 subjects aged between 40 and 75 years and a representative sample of 600 general practitioners (GPs). Information about participating subjects included socio-demographic characteristics, attitude towards CS, and about GPs’ medical practice regarding CS. Results: Only 25% of the 970 subjects aged between 50 and 74 years had undergone a colorectal screening test. In the organized departments (OD), the rate of persons who self-report any colorectal cancer screening was 34% vs 20% in unorganized departments (UD) (OR=1.99, CI95% 1.47- 2.69, p<0.001). The rate of recent screening within a range of 2 years was 24% for OD vs 8% for UD (OR=3.35, CI95% 1.91- 5.88, p<0.01). The rate of “fear of the test and/or its results” was higher in OD: 11% versus 6% (OR=1.97, CI95% 1.11–3.49). The rate of GPs who advocated systematically for screening was 40%, 29%, 26% and 13% for scout, first wave, second wave OD and baseline UD respectively. Organization reduced the rate of screening based on colonoscopy alone from 69% persons in UD to 35% in the OD. Conclusions: The main result of this survey comparing data in the same frame of time, in the same country, is that organized programs for colorectal cancer impact of health outcomes. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- Y. Coscas
- Clinique Porte de St. Cloud, Boulogne-Billancourt, France; Institut Ste Catherine, Avignon, France; Hôpital Font-Pré, Toulon, France; Institut Paoli-Calmettes, Marseille, France; Hôpital Edouard Herriot, Lyon, France; CHU Pitié-Salpétrière, Paris, France; CHU Jean Minjoz, Besançon, France; Hôpital Avicenne, Bobigny, France; Roche, Neuilly sur Seine, France
| | - D. Serin
- Clinique Porte de St. Cloud, Boulogne-Billancourt, France; Institut Ste Catherine, Avignon, France; Hôpital Font-Pré, Toulon, France; Institut Paoli-Calmettes, Marseille, France; Hôpital Edouard Herriot, Lyon, France; CHU Pitié-Salpétrière, Paris, France; CHU Jean Minjoz, Besançon, France; Hôpital Avicenne, Bobigny, France; Roche, Neuilly sur Seine, France
| | - L. Cals
- Clinique Porte de St. Cloud, Boulogne-Billancourt, France; Institut Ste Catherine, Avignon, France; Hôpital Font-Pré, Toulon, France; Institut Paoli-Calmettes, Marseille, France; Hôpital Edouard Herriot, Lyon, France; CHU Pitié-Salpétrière, Paris, France; CHU Jean Minjoz, Besançon, France; Hôpital Avicenne, Bobigny, France; Roche, Neuilly sur Seine, France
| | - F. Eisinger
- Clinique Porte de St. Cloud, Boulogne-Billancourt, France; Institut Ste Catherine, Avignon, France; Hôpital Font-Pré, Toulon, France; Institut Paoli-Calmettes, Marseille, France; Hôpital Edouard Herriot, Lyon, France; CHU Pitié-Salpétrière, Paris, France; CHU Jean Minjoz, Besançon, France; Hôpital Avicenne, Bobigny, France; Roche, Neuilly sur Seine, France
| | - J. Blay
- Clinique Porte de St. Cloud, Boulogne-Billancourt, France; Institut Ste Catherine, Avignon, France; Hôpital Font-Pré, Toulon, France; Institut Paoli-Calmettes, Marseille, France; Hôpital Edouard Herriot, Lyon, France; CHU Pitié-Salpétrière, Paris, France; CHU Jean Minjoz, Besançon, France; Hôpital Avicenne, Bobigny, France; Roche, Neuilly sur Seine, France
| | - O. Rixe
- Clinique Porte de St. Cloud, Boulogne-Billancourt, France; Institut Ste Catherine, Avignon, France; Hôpital Font-Pré, Toulon, France; Institut Paoli-Calmettes, Marseille, France; Hôpital Edouard Herriot, Lyon, France; CHU Pitié-Salpétrière, Paris, France; CHU Jean Minjoz, Besançon, France; Hôpital Avicenne, Bobigny, France; Roche, Neuilly sur Seine, France
| | - X. Pivot
- Clinique Porte de St. Cloud, Boulogne-Billancourt, France; Institut Ste Catherine, Avignon, France; Hôpital Font-Pré, Toulon, France; Institut Paoli-Calmettes, Marseille, France; Hôpital Edouard Herriot, Lyon, France; CHU Pitié-Salpétrière, Paris, France; CHU Jean Minjoz, Besançon, France; Hôpital Avicenne, Bobigny, France; Roche, Neuilly sur Seine, France
| | - T. Bouillet
- Clinique Porte de St. Cloud, Boulogne-Billancourt, France; Institut Ste Catherine, Avignon, France; Hôpital Font-Pré, Toulon, France; Institut Paoli-Calmettes, Marseille, France; Hôpital Edouard Herriot, Lyon, France; CHU Pitié-Salpétrière, Paris, France; CHU Jean Minjoz, Besançon, France; Hôpital Avicenne, Bobigny, France; Roche, Neuilly sur Seine, France
| | - C. Roussel
- Clinique Porte de St. Cloud, Boulogne-Billancourt, France; Institut Ste Catherine, Avignon, France; Hôpital Font-Pré, Toulon, France; Institut Paoli-Calmettes, Marseille, France; Hôpital Edouard Herriot, Lyon, France; CHU Pitié-Salpétrière, Paris, France; CHU Jean Minjoz, Besançon, France; Hôpital Avicenne, Bobigny, France; Roche, Neuilly sur Seine, France
| | - J. Morere
- Clinique Porte de St. Cloud, Boulogne-Billancourt, France; Institut Ste Catherine, Avignon, France; Hôpital Font-Pré, Toulon, France; Institut Paoli-Calmettes, Marseille, France; Hôpital Edouard Herriot, Lyon, France; CHU Pitié-Salpétrière, Paris, France; CHU Jean Minjoz, Besançon, France; Hôpital Avicenne, Bobigny, France; Roche, Neuilly sur Seine, France
| |
Collapse
|
17
|
Bouillet T, Diana C, Pailler M, Gozy M, Labrune S, Gervais R, Brechot J, Breau J, Chinet T, Morere J. P-196 Concurrent chemo-radiotherapy in locally advanced non-smallcell lung cancer (NSCLC): A multicenter randomized phase II study. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80690-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
18
|
Chouahnia K, Des-Guetz G, Bouillet T, Saintigny P, Brechot J, Morère J, Breau J. P-945 Compassional treatment of gefitinib 250 mg/d in patients withnon small cell lung cancer (NSCLC). The Avicenne hospital experience. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)81438-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
19
|
Chouahnia K, Des Guetz G, Bouillet T, Brechot JM, Saintigny P, Casassus P, Morere JF, Breau JL. Retrospective study of compassionnal treatment of gefitinib 250 mg/d in non small cell lung cancer (NSCLC). The Hopital Avicenne experience. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
20
|
Bouillet T, Saintigny P, Levy E, Spano JP, Morin F, Pommeyrol A, Brun B, Bennamoun M, Breau JL, Morère JF. Weekly paclitaxel (P) combined with biweekly vinorelbine (V) in metastatic breast cancer (MBC): Final results of a clinical phase II study. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.783] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- T. Bouillet
- Hopital Avicenne-APHP, Bobigny, France; Hopital Européen Georges Pompidou-APHP, Paris, France; Hopital Pitié-Salpétrière-APHP, Paris, France
| | - P. Saintigny
- Hopital Avicenne-APHP, Bobigny, France; Hopital Européen Georges Pompidou-APHP, Paris, France; Hopital Pitié-Salpétrière-APHP, Paris, France
| | - E. Levy
- Hopital Avicenne-APHP, Bobigny, France; Hopital Européen Georges Pompidou-APHP, Paris, France; Hopital Pitié-Salpétrière-APHP, Paris, France
| | - J.-P. Spano
- Hopital Avicenne-APHP, Bobigny, France; Hopital Européen Georges Pompidou-APHP, Paris, France; Hopital Pitié-Salpétrière-APHP, Paris, France
| | - F. Morin
- Hopital Avicenne-APHP, Bobigny, France; Hopital Européen Georges Pompidou-APHP, Paris, France; Hopital Pitié-Salpétrière-APHP, Paris, France
| | - A. Pommeyrol
- Hopital Avicenne-APHP, Bobigny, France; Hopital Européen Georges Pompidou-APHP, Paris, France; Hopital Pitié-Salpétrière-APHP, Paris, France
| | - B. Brun
- Hopital Avicenne-APHP, Bobigny, France; Hopital Européen Georges Pompidou-APHP, Paris, France; Hopital Pitié-Salpétrière-APHP, Paris, France
| | - M. Bennamoun
- Hopital Avicenne-APHP, Bobigny, France; Hopital Européen Georges Pompidou-APHP, Paris, France; Hopital Pitié-Salpétrière-APHP, Paris, France
| | - J.-L. Breau
- Hopital Avicenne-APHP, Bobigny, France; Hopital Européen Georges Pompidou-APHP, Paris, France; Hopital Pitié-Salpétrière-APHP, Paris, France
| | - J.-F. Morère
- Hopital Avicenne-APHP, Bobigny, France; Hopital Européen Georges Pompidou-APHP, Paris, France; Hopital Pitié-Salpétrière-APHP, Paris, France
| |
Collapse
|
21
|
Affiliation(s)
- K Chouahnia
- Service d'Oncologie Médicale, Hôpital Avicenne - Bobigny
| | | | | | | | | |
Collapse
|
22
|
Bouillet T, Morere J, Despreaux G, Herman D, Corré A, Agranat P, Coulon M, Brunet A, Brunel P, Breau J. Phase II study of paclitaxel (P) twice a week as a radiosensitizer, after paclitaxel-carboplatin (C) induction chemotherapy (IC) in stage IIId–IV head and neck carcinoma (HNC). Eur J Cancer 1999. [DOI: 10.1016/s0959-8049(99)81076-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
23
|
Abstract
PURPOSE The study assessed the efficacy of combination therapy with vinorelbine and ifosfamide in patients with unresectable non-small cell lung cancer. PATIENTS AND METHODS Forty patients with non-small cell lung cancer whose tumour was unresectable by virtue of the extent of disease or severity of impairment of lung function and who were considered unsuitable for treatment with a cisplatin based treatment were entered onto the study. Thirty-four patients received two cycles of treatment and were considered to be evaluable for response. The treatment schedule consisted of vinorelbine (Navelbine, Pierre Fabre Medicament) 25 mg/m2 on days 1 and 8, and ifosfamide 2 g/m2 per day with mesna 0.5 g/m2 three times daily given on days 1 to 3; cycles were repeated every 21 days and treatment continued in responding patients until progression occurred. RESULTS Objective responses were observed in 12 patients (30%; CI95, 16-44) with one completed response (CR) and 11 partial response (PR). CONCLUSION This schedule achieves good levels of response without the use of cisplatin so it is suitable for patients whose performance status or concomitant medical condition precludes the use of platinum based chemotherapy.
Collapse
Affiliation(s)
- J F Morere
- Service d'Oncologie Médicale, CHU Avicenne, Bobigny, France
| | | | | | | | | | | | | |
Collapse
|
24
|
Morere JF, Bouillet T, Piperno-Neumann S, Tourani JM, Brunet A, Hennebelle F, Bareau JL. [Treatment of advanced kidney cancer using recombinant erythropoietin]. Prog Urol 1997; 7:399-402. [PMID: 9273066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
OBJECTIVES Study of the antitumour effects of erythropoietin on metastatic renal cell carcinoma. METHODS After giving their informed consent, 20 patients with histologically proven metastatic renal cell carcinoma received subcutaneous recombinant erythropoietin three times a day at a dose of 150 IU/kg when haemoglobin was less than or equal to 12 g/dL or 75 IU/kg when haemoglobin was higher than 12 g/dL. Treatment was continued for a minimum of 8 weeks before reassessment and was continued thereafter, except in the case of progression or excessive toxicity. A staging assessment was performed every 8 weeks and the response was assessed on the basis of WHO criteria. A clinical and laboratory assessment was performed every two months to evaluate toxicity, graded according to the WHO scale. All but one of the patients had received immunotherapy or chemotherapy prior to inclusion in the study. RESULTS One complete response (> 12 months), one partial response (8 months), two minor responses, 10 cases of stabilisation and 6 cases of progression were observed. 15 patients received treatment at full doses. In 5 patients, the duration of treatment was reduced before the 8 weeks initially defined because of tumour progression in one patient and because of haemoglobin persistently greater than 15 g/dL in 4 other patients. Adverse effects consisted of 1 case of moderate headache, 2 cases of transient bone pain, and 1 case of transient hypertension. CONCLUSION Erythropoietin exerts a moderate antitumour effect which needs to be confirmed by a phase II trial of first-line treatment in selected patients.
Collapse
Affiliation(s)
- J F Morere
- Service d'Oncologie Médicale, CHU Avicenne, Bobigny, France
| | | | | | | | | | | | | |
Collapse
|
25
|
Bouillet T, Morère JF, Mazeron JJ, Piperno-Neuman S, Boaziz C, Haddad E, Breau JL. [Induction chemotherapy followed by concomitant combined radiotherapy and chemotherapy in stage III non-small cell bronchial carcinoma]. Cancer Radiother 1997; 1:121-31. [PMID: 9273182 DOI: 10.1016/s1278-3218(97)83528-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
PURPOSE To determine the efficacy and safety of induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of stage III non-small cell lung cancer and whether the response to induction chemotherapy can predict the response to subsequent chemoradiotherapy and survival. MATERIALS AND METHODS Between December 1987 and June 1993, 46 patients with previously untreated stage III non-small cell lung cancer received every 21 days induction chemotherapy (ICT) including three cycles of 5-fluorouracil (600 mg/m2/d in short infusion from d1 to d5), cisplatin (15 mg/m2/d from d1 to d5), etoposide (50 mg/m2/d from d1 to d5) and hydroxyurea (1,500 mg/d from d1 to d5). The first 21 patients also received bleomycin (3 mg/m2/d from d1 to d5). All patients received concomitant chemotherapy and had chest radiotherapy (CCRT). Patients received irradiation (65 Gy/33-6 fractions/7 weeks) on d25 after the third cycle of chemotherapy. Concomitant chemotherapy was composed of cisplatin (20 mg/m2) and 5-fluorouracil (500 mg/m2) that were administered each Monday and Thursday during radiotherapy. Maintenance chemotherapy consisted of thiotepa (10 mg/m2) and methotrexate (10 mg/m2) that were administered every 2 weeks for 6 months. RESULTS Pulmonary toxicity was observed in four out of 21 patients who had received bleomycin and subsequently developed pulmonary fibrosis, leading to death for two of them. ICT alone produced five complete responses (11%) and 13 partial responses (28%). The combination of chemotherapy and radiotherapy led to 19 complete responses (41%) and 14 partial responses (30%). Eighteen of the 18 responders (100%) to ICT responded to subsequent CCRT, of whom 13 (72%) became complete responders. Fifteen of the 28 non-responders to ICT (53%) responded to CCRT, six of them being complete responders (21%) (P < 0.001). The median overall survival rate was 17 months when considering all patients, 25 months in patients responding to ICT and 13 months in non-responders. The 2-year survival rates were 28, 55 and 11%, respectively (P < 0.05). ICT did not influence the rate of subsequent metastatic events. However, locoregional reprogression was lower in responders to ICT. The number of metastatic events was not significantly related to response to ICT. By contrast, the rate of local failure was higher when there was resistance to ICT (75% versus 39%). Out of the 19 complete responders to CCRT (13 responders to ICT and six non-responders to ICT), four developed secondary locoregional reprogression (21%) and six developed metastatic disease (31%). In complete responders to CCRT, the rate of locoregional failure was 15% in responders to ICT (2/13) and 33% (2/6) in non-responders to ICT. Four out of the 13 responders to CCRT after response to ICT (31%) and two out of the six complete responders to CCRT developed metastatic disease after non-response to ICT. CONCLUSION There is a statistically significant relationship not only between the response to ICT and the response to CCRT, but also between the response to ICT and the local outcome and survival.
Collapse
MESH Headings
- Adenocarcinoma/drug therapy
- Adenocarcinoma/pathology
- Adenocarcinoma/radiotherapy
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols/adverse effects
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Carcinoma, Bronchogenic/drug therapy
- Carcinoma, Bronchogenic/pathology
- Carcinoma, Bronchogenic/radiotherapy
- Carcinoma, Non-Small-Cell Lung/drug therapy
- Carcinoma, Non-Small-Cell Lung/pathology
- Carcinoma, Non-Small-Cell Lung/radiotherapy
- Carcinoma, Squamous Cell/drug therapy
- Carcinoma, Squamous Cell/pathology
- Carcinoma, Squamous Cell/radiotherapy
- Combined Modality Therapy
- Drug Administration Schedule
- Female
- Humans
- Lung Neoplasms/drug therapy
- Lung Neoplasms/pathology
- Lung Neoplasms/radiotherapy
- Male
- Middle Aged
- Neoplasm Metastasis
- Neoplasm Recurrence, Local
- Neoplasm Staging
- Radiotherapy Dosage
- Survival Rate
Collapse
Affiliation(s)
- T Bouillet
- Service d'oncologie, hôpital Avicenne, Bobigny, France
| | | | | | | | | | | | | |
Collapse
|
26
|
Breau J, Bouillet T, Mazeron J, Morere J, Piperno-Neuman S, Boaziz C, Haddad E. 1089 Induction chemotherapy (IndCT) and concurrent bi weekly infusion of 5 FU and cisplatin (CDDP) combined with concomitant chest irradiation (CCRT) in locally advanced non-small cell lung cancer (NSCLC). Eur J Cancer 1995. [DOI: 10.1016/0959-8049(95)96335-b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
27
|
Bouillet T, Bloch P. 5 Fluorouracil, etoposide, epirubicin, cisplatin in treatment of advanced gastric cancer. Eur J Cancer 1993. [DOI: 10.1016/0959-8049(93)91191-m] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
28
|
Maylin C, Clot P, Douard MC, Eurin B, Servant JM, Bouillet T, Leduc A, Celerier M. [Peroperative open-air radiotherapy in 1988]. Pathol Biol (Paris) 1989; 37:152-3. [PMID: 2652069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- C Maylin
- Service de Radiothérapie, Hôpital Saint-Louis, Paris, France
| | | | | | | | | | | | | | | |
Collapse
|